Familial hypercholesterolaemia

Familial hypercholesterolaemia (FH) is a monogenic disorder of low-density lipoprotein (LDL) metabolism. It is characterised by markedly elevated LDL cholesterol, autosomal dominant inheritance, premature cardiovascular disease and tendon xanthomata. FH is a genetically heterogeneous disorder, but t...

Full description

Saved in:
Bibliographic Details
Main Author: D.J. Blom
Format: Article
Language:English
Published: AOSIS 2011-01-01
Series:South African Family Practice
Subjects:
Online Access:https://safpj.co.za/index.php/safpj/article/view/1629
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849340833810087936
author D.J. Blom
author_facet D.J. Blom
author_sort D.J. Blom
collection DOAJ
description Familial hypercholesterolaemia (FH) is a monogenic disorder of low-density lipoprotein (LDL) metabolism. It is characterised by markedly elevated LDL cholesterol, autosomal dominant inheritance, premature cardiovascular disease and tendon xanthomata. FH is a genetically heterogeneous disorder, but the most common underlying molecular cause is mutation of the LDL receptor gene. The worldwide prevalence of FH is 1:500. South Africa has three founder populations in which the prevalence of FH may be as high as 1:70. FH is diagnosed clinically, but the diagnosis can be confirmed by DNA analysis. DNA testing cannot always identify the causative mutation because there are several genes to examine and more than 1 500 different mutations have been identified in the LDL receptor alone. Statins are the treatment of choice for patients with FH. Ezetimibe or cholestyramine can be added if additional LDL lowering is required, or if patients are unable to tolerate high statin doses.
format Article
id doaj-art-00fe8a7f4a4a4d87993d9b09e4265710
institution Kabale University
issn 2078-6190
2078-6204
language English
publishDate 2011-01-01
publisher AOSIS
record_format Article
series South African Family Practice
spelling doaj-art-00fe8a7f4a4a4d87993d9b09e42657102025-08-20T03:43:47ZengAOSISSouth African Family Practice2078-61902078-62042011-01-0153110.1080/20786204.2011.108740544535Familial hypercholesterolaemiaD.J. Blom0Division of Lipidology, Department of Medicine, University of Cape TownFamilial hypercholesterolaemia (FH) is a monogenic disorder of low-density lipoprotein (LDL) metabolism. It is characterised by markedly elevated LDL cholesterol, autosomal dominant inheritance, premature cardiovascular disease and tendon xanthomata. FH is a genetically heterogeneous disorder, but the most common underlying molecular cause is mutation of the LDL receptor gene. The worldwide prevalence of FH is 1:500. South Africa has three founder populations in which the prevalence of FH may be as high as 1:70. FH is diagnosed clinically, but the diagnosis can be confirmed by DNA analysis. DNA testing cannot always identify the causative mutation because there are several genes to examine and more than 1 500 different mutations have been identified in the LDL receptor alone. Statins are the treatment of choice for patients with FH. Ezetimibe or cholestyramine can be added if additional LDL lowering is required, or if patients are unable to tolerate high statin doses.https://safpj.co.za/index.php/safpj/article/view/1629familial hypercholesterolaemialow-density lipoprotein receptorapolipoprotein b100pcsk9tendon xanthomata
spellingShingle D.J. Blom
Familial hypercholesterolaemia
South African Family Practice
familial hypercholesterolaemia
low-density lipoprotein receptor
apolipoprotein b100
pcsk9
tendon xanthomata
title Familial hypercholesterolaemia
title_full Familial hypercholesterolaemia
title_fullStr Familial hypercholesterolaemia
title_full_unstemmed Familial hypercholesterolaemia
title_short Familial hypercholesterolaemia
title_sort familial hypercholesterolaemia
topic familial hypercholesterolaemia
low-density lipoprotein receptor
apolipoprotein b100
pcsk9
tendon xanthomata
url https://safpj.co.za/index.php/safpj/article/view/1629
work_keys_str_mv AT djblom familialhypercholesterolaemia